Insmed could end up with another blockbuster on its hands Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 23 March, 2026

Every year, John Carroll sizes up the top 15 global pharma pipelines — then brings the findings live with the R&D chiefs shaping them. What's in, what's out, and what's next for 2026? Register now.

presented by Fu­ji­film ex­pands glob­al life sci­ences foot­print through large-scale bio­man­u­fac­tur­ing in­vest­ments

news A California startup wins $180M in support as Sanofi rebuilds presence in T cell engagers Lack of cases hampers Pfizer’s Phase 3 Lyme disease vaccine trial Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection Apogee’s Phase 2 data show its eczema drug could have the convenience edge over Dupixent, Ebglyss

Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

endpoints pharma UK’s NICE revisits Lilly, Eisai Alzheimer's drugs in time for new pricing threshold Top HHS official on TrumpRx: ‘The goal was not actually some massive reach’ FDA seeks input on Makary's pilot drug approval accelerator Peer Review Idorsia looks for another CEO — again; Former Jazz exec makes a comeback

in case you missed it 1. AI biotech Earendil announces huge $787M raise, is reportedly considering Hong Kong IPO 2. Novo Holdings' CEO is losing no sleep over asset drop but geopolitics are gnawing at him 3. Updated: Novartis adds fuel to breast cancer drug race in $2B upfront buy of next-gen PI3Kα inhibitor 4. Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial 5. News Briefing Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity 6. Big drugmakers saved at least $5bn on US taxes shifting income overseas 7.